Liu et al. 2019 (PRJNA476979)

General Details

Title The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [ribosome profiling]
Organism
Number of Samples 10
Release Date 2018/06/20 00:00
Sequencing Types
Protocol Details

Study Links

Repository Details

SRA SRP151006
ENA SRP151006
GEO GSE116082
BioProject PRJNA476979

Publication

Title
Authors Liu Y,Horn JL,Banda K,Goodman AZ,Lim Y,Jana S,Arora S,Germanos AA,Wen L,Hardin WR,Yang YC,Coleman IM,Tharakan RG,Cai EY,Uo T,Pillai SPS,Corey E,Morrissey C,Chen Y,Carver BS,Plymate SR,Beronja S,Nelson PS,Hsieh AC
Journal Science translational medicine
Publication Date 2019 Jul 31
Abstract The androgen receptor (AR) is a driver of cellular differentiation and prostate cancer development. An extensive body of work has linked these normal and aberrant cellular processes to mRNA transcription; however, the extent to which AR regulates posttranscriptional gene regulation remains unknown. Here, we demonstrate that AR uses the translation machinery to shape the cellular proteome. We show that AR is a negative regulator of protein synthesis and identify an unexpected relationship between AR and the process of translation initiation in vivo. This is mediated through direct transcriptional control of the translation inhibitor 4EBP1. We demonstrate that lowering AR abundance increases the assembly of the eIF4F translation initiation complex, which drives enhanced tumor cell proliferation. Furthermore, we uncover a network of pro-proliferation mRNAs characterized by a guanine-rich cis-regulatory element that is particularly sensitive to eIF4F hyperactivity. Using both genetic and pharmacologic methods, we demonstrate that dissociation of the eIF4F complex reverses the proliferation program, resulting in decreased tumor growth and improved survival in preclinical models. Our findings reveal a druggable nexus that functionally links the processes of mRNA transcription and translation initiation in an emerging class of lethal AR-deficient prostate cancer. Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
PMC PMC6746573
PMID 31366581
DOI
Run Accession Study Accession Scientific Name Cell Line Library Type Treatment GWIPS-viz Trips-Viz Reads BAM BigWig (F) BigWig (R)
SRR7405198 PRJNA476979 Mus musculus RNA-Seq
SRR7405199 PRJNA476979 Mus musculus Ribo-Seq
SRR7405200 PRJNA476979 Mus musculus RNA-Seq
SRR7405201 PRJNA476979 Mus musculus Ribo-Seq
SRR7405202 PRJNA476979 Mus musculus RNA-Seq
SRR7405203 PRJNA476979 Mus musculus Ribo-Seq
SRR7405204 PRJNA476979 Mus musculus RNA-Seq
SRR7405205 PRJNA476979 Mus musculus Ribo-Seq
SRR7405206 PRJNA476979 Mus musculus RNA-Seq
SRR7405207 PRJNA476979 Mus musculus Ribo-Seq
Run Accession Study Accession Scientific Name Cell Line Library Type Treatment GWIPS-viz Trips-Viz Reads BAM BigWig (F) BigWig (R)

ⓘ For more Information on the columns shown here see: About